Status:

COMPLETED

Pro-thrombotic Status in Patients with SARS-Cov-2 Infection

Lead Sponsor:

University Hospital of Ferrara

Conditions:

Severe Acute Respiratory Syndrome Coronavirus 2

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure...

Detailed Description

Preliminary evidences suggested that patients with SARS-Cov-2 infection and concomitant presence of cardiovascular risk factors (i.e. arterial hypertension) and/or cardiovascular history (i.e. prior m...

Eligibility Criteria

Inclusion

  • Diagnosis of moderate-severe respiratory failure (PaO2/FiO2 \<200)
  • Diagnosis of SARS-CoV-2 infection + one of the following
  • invasive mechanical ventilation (cohort A)
  • non invasive mechanical ventilation (cohort B)
  • only oxygen support

Exclusion

  • Previous chronic use of P2Y12 inhibitors
  • Need for chronic oral anti-coagulation therapy
  • Know disorder of coagulation or platelet function

Key Trial Info

Start Date :

April 8 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 7 2024

Estimated Enrollment :

145 Patients enrolled

Trial Details

Trial ID

NCT04343053

Start Date

April 8 2020

End Date

December 7 2024

Last Update

December 12 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Azienda Ospedaliera Universitaria di Ferrara

Ferrara, Italy